Antitumor Activity of NMS-P937 Specific Small-Molecule Polo-Like Kinase 1 Inhibitor, in PC3 Human Prostate Cancer, Hela Cervical Cancer, and SKOV-3 Ovarian Cancer Cell Lines

Basit Öğe Kaydı
dc.contributor.authorYurtçu, Nazan
dc.contributor.authorGökhan, Aylin
dc.date.accessioned2024-10-26T17:42:41Z
dc.date.available2024-10-26T17:42:41Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: We aimed to investigate the antitumor activity of NMS-P937, a specific small-molecule polo-like kinase 1 (PLK1) inhibitor, in PC3 human prostate cancer, HeLa cervical cancer, and SKOV-3 ovarian cancer cell lines. Materials and methods: PC3, HeLa, and SKOV-3 cells were treated with NMS-P937 for 48 h. The viability was analyzed by XTT colorimetric assay. Since PC3 was found to be the most sensitive cell line, total oxidant status (TOS) values were evaluated in NMS-P937-treated and non-treated PC3 cells via TOS assay. Results: The proliferation of cancer cell lines was moderately inhibited by NMS-P937 in conjunction with the increase in concentration. The IC50 values of NMS-P937 in PC3, HeLa, and SKOV-3 cells were recorded as 27.3, 69.7, and 79.3 ?M, respectively, for 48 h. TOS was measured in control and NMS-P937-treated PC3 cells and calculated as 3.15±0.36 and 4.49±0.64 ?mol H2O2 Equiv./L, respectively, indicating the increased oxidative stress under the influence of the study compound (p=0.035). Conclusion: The PLK1 inhibitor NMS-P937 reduces the activity of cancer cell lines consisting of PC3 human prostate cancer, HeLa cervical cancer, and SKOV-3 ovarian cancer in a dose-dependent manner. This compound increases oxidative stress, which may play a pivotal role in the cytotoxic activity of the compound in PC3 cells. However, there is still a need to carry out both in vitro and in vivo studies, including different cancer cell lines and tumor models, and to reveal the adverse effects that may develop.
dc.identifier.doi10.46332/aemj.960806
dc.identifier.endpage12
dc.identifier.issn2619-9203
dc.identifier.issue1
dc.identifier.startpage6
dc.identifier.trdizinid1163962
dc.identifier.urihttps://doi.org/10.46332/aemj.960806
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1163962
dc.identifier.urihttps://hdl.handle.net/20.500.12418/24766
dc.identifier.volume7
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofAhi Evran Medical Journal
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCytotoxicity
dc.subjectoxidative stress
dc.subjectcancer cell lines
dc.subjectNMS-P937
dc.subjectPLK1 inhibition
dc.titleAntitumor Activity of NMS-P937 Specific Small-Molecule Polo-Like Kinase 1 Inhibitor, in PC3 Human Prostate Cancer, Hela Cervical Cancer, and SKOV-3 Ovarian Cancer Cell Lines
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu